Guest guest Posted August 14, 1999 Report Share Posted August 14, 1999 In a message dated 7/30/99 1:44:26 PM Eastern Daylight Time, pattymcd@... writes: > Hi Sharon, > > I took 2 doses of Celexa (at bedtime) - for pain & sleeping. I had a > really weird feeling too - can't explain it exactly, but strange. It > also affected my vision senses - objects I looked at seem to pulsate! > UGH! And in the morning, my whole body, especially my hands, trembled. > I called my LLD and he said to stop the Celexa - some just can't handle > it and I guess I'm one of them. I hope the weird " feelings " stop for > you since it is helping so much with your energy. > > Patty Hi Sharon just curious, how much were you on? best, lea Quote Link to comment Share on other sites More sharing options...
Guest guest Posted October 20, 1999 Report Share Posted October 20, 1999 In a message dated 10/20/99 7:31:48 PM EDT, mellillo1@... writes: << , I used to be the same way on all the other antidepressents, Effexor too. Went through them all for the past 6 years. Finally, this spring went on Celexa. I don't cry anymore unless it is a big thing. It is wonderful! I used to be so embarrassed, I would lose it at the wrong time, in the wrong place and couldn't stop. Now, even when I brought my precious daughter to college, I was able to stay in control and only shed a few tears. I had asked my dr. specifically for something to stop the crying jags. So maybe you might want to check into it. It also helps the dead libido problem that many of the antid's give you. I finally have a little sex drive which I havent' in years. Congrats on your son's wedding. In this day and age it is nice to see >> Hi Guys, Hope everyone is well . I am reading so much about Celexa on here, but am wondering if any of you who are on celexa have gained any weight from it ?? It sounds great , but I can't afford to gain the weight. Thanks in advance for your response Quote Link to comment Share on other sites More sharing options...
Guest guest Posted October 21, 1999 Report Share Posted October 21, 1999 Actually no, I have not gained weight. But, then one has to eat to gain weight! I don't have any hunger at all and eat when my hubby puts something in front of me and not before. The only time I had an appetite to speak of in the last year or so was when I was on the Rocephin IV and so many symptoms started changing that were positive. But, cannot get $^%^^ insurance company to let me have them again so possibly go into remission. Slowly the symptoms are returning....but, thus far a bit better than before. The worst of the symptoms pain, fatigue (really exhaustion), and difficulty breathing (asthma) remain unchanged. If it weren't for the jackass Alan Steere's in this world spewing their mantra of over diagnosed and over treated, the people with Lyme Disease would not be refused the necessary medical treatment we need. Grr.... BearyPrety@... wrote: > From: BearyPrety@... > > In a message dated 10/20/99 7:31:48 PM EDT, mellillo1@... writes: > > << , I used to be the same way on all the other antidepressents, > Effexor too. Went through them all for the past 6 years. Finally, this > spring went on Celexa. I don't cry anymore unless it is a big thing. It is > wonderful! I used to be so embarrassed, I would lose it at the wrong time, > in the wrong place and couldn't stop. Now, even when I brought my precious > daughter to college, I was able to stay in control and only shed a few > tears. I had asked my dr. specifically for something to stop the crying > jags. So maybe you might want to check into it. It also helps the dead > libido problem that many of the antid's give you. I finally have a little > sex drive which I havent' in years. > Congrats on your son's wedding. In this day and age it is nice to see >> > > Hi Guys, > Hope everyone is well . I am reading so much about Celexa on here, but am > wondering if any of you who are on celexa have gained any weight from it ?? > It sounds great , but I can't afford to gain the weight. > Thanks in advance for your response > > > > Send to -Offtopiconelist messages unrelated to lyme, please. > /archive/lyme-aid > /archives.cgi/Lyme-Documents > To unsubscribe, send email to -unsubscribeonelist > You may substitute " subscribe " , or " digest " or " normal " for > the word " unsubscribe " ( " normal " is the opposite of " digest " ). Leave blank both the message and subject header. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted October 22, 1999 Report Share Posted October 22, 1999 I swear by low carb. I guess I'm in between Atkins and Protein Power. I just love it. Hope it helps you, good luck!! Anita [Lyme-aid] celexa >From: " melillo " <mellillo1@...> > >diana, i have not gained weight on the celexa but i have not lost weight >either. the positive is that i am not crying and eating out of comfort >seeking. so, maybe in the long run it will help the obsessive urge i have >to eat. >interestingly, i started to cut back on carbos this week and it has helped >my appetite. i saw a blurb on oprah about carbo addicts and thought it >sounded like me. so i read the book, " carbohydrate addicts diet " by the >hellers. it made sense for me individually. so i have been trying to >follow it for a week. i'll let you know how it goes but my hunger is >diminished. i tried atkins a while ago but it was too much meat! >i am now on plaquenil and i don't know why but all i want to do is sleep. i >slept 14 hours yesterday and could go back to bed now. weird! >sharon > >>Send to -Offtopiconelist messages unrelated to lyme, please. >/archive/lyme-aid >/archives.cgi/Lyme-Documents >To unsubscribe, send email to -unsubscribeonelist >You may substitute " subscribe " , or " digest " or " normal " for >the word " unsubscribe " ( " normal " is the opposite of " digest " ). Leave blank both the message and subject header. > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted April 8, 2000 Report Share Posted April 8, 2000 Hi, connie, Glad you are feeling better. I hope this will last elizabeth Quote Link to comment Share on other sites More sharing options...
Guest guest Posted April 9, 2000 Report Share Posted April 9, 2000 Thanks ..............I just hope it continues............I felt a little tired today.............Connie Quote Link to comment Share on other sites More sharing options...
Guest guest Posted July 5, 2000 Report Share Posted July 5, 2000 Eliza: My son takes 40 mg of Celexa, and it seems to work pretty well for him. Unfortunately, the medication and/or dosage that works for one individual may be completely ineffective in another. Ditto for BSEs. Aiden had been on 60 mg of Prozac, the same as my 6'1 " husband -- and he is turning 12 at the end of the month. I would discuss your concerns with the prescribing physician before coming to any conclusion. Remember, to be effective in treating OCD, the meds have to be prescribed in higher doses than in treatment of depression. Also keep in mind that children have higher metabolic rates than adults and therefore process the meds quicker -- i.e. they enter and leave the system faster. Hope this helps. Jule in Cleveland Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 3, 2000 Report Share Posted November 3, 2000 My son recently titered off Prozac (40 mg.) and on to Celexa. We started with 20 mg. in the hopes that less is better. Within a 6 week period and 20 mg. later it became clear that Celexa was not the way to go for him. All of his sensory issues returned along with OCD symptoms that we had not seen in 2 years. We have not had experience with anafranil yet, so I can't speak to that medication. We had a VERY HYPERACTIVE reaction to Paxil. Medication stuff can be so tricky. I always have to gear myself up for medication changes...I do not like the fact that my child must try different medications in order to find the best combination. --- Judy Lovchik <jlovchik@...> wrote: > Jule and others experienced with Celexa: > > My 15 yo son is titering up on Celexa and titering > down on anafranil. After 2 weeks, he is up to 40mg > Celexa and down to 25mg anafranil. He's very > depressed and extremely anxious. I added another > 10mg Celexa yesterday, but he became even worse, so > I'll stay at 40 awhile longer. Jule, how much > Celexa is Aiden taking? And how much Wellbutrin and > Risperodol? I'm going to suggest them to his > doctor. > > Judy > Re: advice please > > > > > Nan: > > My son (now 12) had terrible BSE's from Luvox -- > not at first, but after a > couple months he became oppositional and > aggressive, something he had NEVER > been. He was then placed on Prozac with good > results until it pooped out this > spring and we had to switch to Celexa. He also > has ADHD, and depression. In > unipolar depression people may suffer from > repeated episodes of depression. > However, their mood returns to normal at the end > of an episode of depression. > > Aiden also takes Risperdal and Wellbutrin as an > adjunct to the Celexa. He has a > great deal of anxiety on top of the ocd, and the > Risperdal helps to keep him > under better control. The Wellbutrin is to boost > the antidepressant effect of > the Celexa. Currently he is not taking anything > for the ADHD, although he has > been on Adderall and Ritalin in the past. I think > that perhaps the Risperdal > helps with some of the inattentiveness. > > As a side note to Noelle: Aiden took 60 mg of > Prozac -- our shrink did not want > to put him up any higher due to the greatly > increase risk of side effects such > as tremors and stomach problems. That is why we > opted to change SSRIs, and > we've been happy with the Celexa. > > Jule > > > > You may subscribe to the OCD-L by emailing > listserv@... . In the body of your > message write: subscribe OCD-L your name. You may > subscribe to the Parents of Adults with OCD List at > parentsofadultswithOCD > . You may access the files, links, and archives > for our list at > . Our > list advisors are Tamar Chansky, Ph.D., and Aureen > Pinto Wagner, Ph.D. Our list moderators are > Birkhan, Kathy Hammes, Jule Monnens, Gail Pesses, > Kathy , Roman, and Jackie Stout. > Subscription issues, problems, or suggestions may be > addressed to Louis Harkins, list owner, at > harkins@... . > > > > __________________________________________________ Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 3, 2000 Report Share Posted November 3, 2000 My son recently titered off Prozac (40 mg.) and on to Celexa. We started with 20 mg. in the hopes that less is better. Within a 6 week period and 20 mg. later it became clear that Celexa was not the way to go for him. All of his sensory issues returned along with OCD symptoms that we had not seen in 2 years. We have not had experience with anafranil yet, so I can't speak to that medication. We had a VERY HYPERACTIVE reaction to Paxil. Medication stuff can be so tricky. I always have to gear myself up for medication changes...I do not like the fact that my child must try different medications in order to find the best combination. --- Judy Lovchik <jlovchik@...> wrote: > Jule and others experienced with Celexa: > > My 15 yo son is titering up on Celexa and titering > down on anafranil. After 2 weeks, he is up to 40mg > Celexa and down to 25mg anafranil. He's very > depressed and extremely anxious. I added another > 10mg Celexa yesterday, but he became even worse, so > I'll stay at 40 awhile longer. Jule, how much > Celexa is Aiden taking? And how much Wellbutrin and > Risperodol? I'm going to suggest them to his > doctor. > > Judy > Re: advice please > > > > > Nan: > > My son (now 12) had terrible BSE's from Luvox -- > not at first, but after a > couple months he became oppositional and > aggressive, something he had NEVER > been. He was then placed on Prozac with good > results until it pooped out this > spring and we had to switch to Celexa. He also > has ADHD, and depression. In > unipolar depression people may suffer from > repeated episodes of depression. > However, their mood returns to normal at the end > of an episode of depression. > > Aiden also takes Risperdal and Wellbutrin as an > adjunct to the Celexa. He has a > great deal of anxiety on top of the ocd, and the > Risperdal helps to keep him > under better control. The Wellbutrin is to boost > the antidepressant effect of > the Celexa. Currently he is not taking anything > for the ADHD, although he has > been on Adderall and Ritalin in the past. I think > that perhaps the Risperdal > helps with some of the inattentiveness. > > As a side note to Noelle: Aiden took 60 mg of > Prozac -- our shrink did not want > to put him up any higher due to the greatly > increase risk of side effects such > as tremors and stomach problems. That is why we > opted to change SSRIs, and > we've been happy with the Celexa. > > Jule > > > > You may subscribe to the OCD-L by emailing > listserv@... . In the body of your > message write: subscribe OCD-L your name. You may > subscribe to the Parents of Adults with OCD List at > parentsofadultswithOCD > . You may access the files, links, and archives > for our list at > . Our > list advisors are Tamar Chansky, Ph.D., and Aureen > Pinto Wagner, Ph.D. Our list moderators are > Birkhan, Kathy Hammes, Jule Monnens, Gail Pesses, > Kathy , Roman, and Jackie Stout. > Subscription issues, problems, or suggestions may be > addressed to Louis Harkins, list owner, at > harkins@... . > > > > __________________________________________________ Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 4, 2000 Report Share Posted November 4, 2000 Judy: Aiden takes 40 mg of Celexa, 2 mg of Risperdal in a split dose, and 150 mg of Wellbutrin. I have to tell you, though, that the month we spent tapering off Prozac and up on Celexa was awful -- just like you're describing with your son. After about 4 weeks we saw a great deal of improvement. That was in the spring. I have tried several times to lower his Risperdal dose, but he gets too anxious when I go lower than the 2 mg. We added Wellbutrin last month due to increased depression. Give the Celexa a chance to work, but do ask the doc about adding something to supplement. He might want to wait until your son has been on the Celexa a couple more weeks. Jule Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 7, 2000 Report Share Posted November 7, 2000 Can someone tell me about Celexa? I havebeen hearing a lot about it recently an d only recently heard the name . Terry Re: celexa > > > Judy: > > Aiden takes 40 mg of Celexa, 2 mg of Risperdal in a split dose, and 150 mg of > Wellbutrin. I have to tell you, though, that the month we spent tapering off > Prozac and up on Celexa was awful -- just like you're describing with your son. > After about 4 weeks we saw a great deal of improvement. That was in the spring. > I have tried several times to lower his Risperdal dose, but he gets too anxious > when I go lower than the 2 mg. We added Wellbutrin last month due to increased > depression. Give the Celexa a chance to work, but do ask the doc about adding > something to supplement. He might want to wait until your son has been on the > Celexa a couple more weeks. > > > Jule > > > > > You may subscribe to the OCD-L by emailing listserv@... . In the body of your message write: subscribe OCD-L your name. You may subscribe to the Parents of Adults with OCD List at parentsofadultswithOCD . You may access the files, links, and archives for our list at . Our list advisors are Tamar Chansky, Ph.D., and Aureen Pinto Wagner, Ph.D. Our list moderators are Birkhan, Kathy Hammes, Jule Monnens, Gail Pesses, Kathy , Roman, and Jackie Stout. Subscription issues, problems, or suggestions may be addressed to Louis Harkins, list owner, at harkins@... . > > > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 7, 2000 Report Share Posted November 7, 2000 Can someone tell me about Celexa? I havebeen hearing a lot about it recently an d only recently heard the name . Terry Re: celexa > > > Judy: > > Aiden takes 40 mg of Celexa, 2 mg of Risperdal in a split dose, and 150 mg of > Wellbutrin. I have to tell you, though, that the month we spent tapering off > Prozac and up on Celexa was awful -- just like you're describing with your son. > After about 4 weeks we saw a great deal of improvement. That was in the spring. > I have tried several times to lower his Risperdal dose, but he gets too anxious > when I go lower than the 2 mg. We added Wellbutrin last month due to increased > depression. Give the Celexa a chance to work, but do ask the doc about adding > something to supplement. He might want to wait until your son has been on the > Celexa a couple more weeks. > > > Jule > > > > > You may subscribe to the OCD-L by emailing listserv@... . In the body of your message write: subscribe OCD-L your name. You may subscribe to the Parents of Adults with OCD List at parentsofadultswithOCD . You may access the files, links, and archives for our list at . Our list advisors are Tamar Chansky, Ph.D., and Aureen Pinto Wagner, Ph.D. Our list moderators are Birkhan, Kathy Hammes, Jule Monnens, Gail Pesses, Kathy , Roman, and Jackie Stout. Subscription issues, problems, or suggestions may be addressed to Louis Harkins, list owner, at harkins@... . > > > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 8, 2000 Report Share Posted November 8, 2000 Hi Vivian: What good news that J. is taking Celexa. It is amazing how the SSRIs can take the edge of symptoms enough to really allow CBT (with E & RP) to proceed. Good luck, I can't wait for your next update. You deserve more good news. Take care, aloha, Kathy (H) kathyh@... At 04:39 AM 11/09/2000 -0000, you wrote: > > Since we are new to this drug, I thought I would post what I >know of it so far. The name of it is CITALOPRAM (sye TAL oh pram) >with the U.S. brand name being 'Celexa'. It is used to treat >depression. It is an SSRI. It inhibits the reuptale of a chemical in >the brain called serotonin. > Our son is taking it in the morning (on a full stomach) as it >can cause nausea and inability to sleep. Some people can feel tired >though, an example of how, as with all meds., some folks react >differently. It can cause anxiety, and a change in sexual ability or >desire. It is not supposed to be habit forming or cause wieght gain. > We were told that these symtoms could improve after taking it >for awhile. (4-6 weeks) Our son started out slow. 10mg for 6 days >(1/2 a tablet) then uped it to one tab. 20mg. He will stay at that >until we see the Dr. for a follow up on Nov. 21st. I guess it comes >in 20mg and 40mg doses. > Some of the things I have seen in J. are giddyness,and not >as irritable. When he increased to 20mg he seemed to be tired and was >more irritable , but >I can't tell if it was from a class situation (assignment due) in >school or not. > I will let you know how this goes, it is still very new to >us. I am just thankful that J is willng to try this, as it has taken >alot of courage on his part, but I can't help but think that he >deserves to be free of this and that our family deserves it too! > Vivian in wa.st. > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 9, 2000 Report Share Posted November 9, 2000 Vivian, Yes, you all deserve to to be free of the control that J's OCD,..., has over you!!! This is a nerve wracking time for all of you! Keep us posted, and dont forget to take care of yourself!! wendy, in canada ======================== > I will let you know how this goes, it is still very new to >us. I am just thankful that J is willng to try this, as it has taken >alot of courage on his part, but I can't help but think that he >deserves to be free of this and that our family deserves it too! > Vivian in wa.st. _________________________________________________________________________ Get Your Private, Free E-mail from MSN Hotmail at http://www.hotmail.com. Share information about yourself, create your own public profile at http://profiles.msn.com. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted March 20, 2001 Report Share Posted March 20, 2001 Alley pat, You are a wonder!!!! Where did you find this study? It is very interesting and actually made me feel better about Celexa. sounds like the sides are kinder and gentler than other anti-deps! As usual, my friends here on the list are wonderful!!!!! Thank you so much. Staying Positive, Lora Quote Link to comment Share on other sites More sharing options...
Guest guest Posted March 20, 2001 Report Share Posted March 20, 2001 Alley pat, You are a wonder!!!! Where did you find this study? It is very interesting and actually made me feel better about Celexa. sounds like the sides are kinder and gentler than other anti-deps! As usual, my friends here on the list are wonderful!!!!! Thank you so much. Staying Positive, Lora Quote Link to comment Share on other sites More sharing options...
Guest guest Posted March 20, 2001 Report Share Posted March 20, 2001 Hey Lora, I took Celexa for a while. I was on treatment and it didn't seem like it was enough for me so I changed. But it is right for many people and from what I've heard, has very few sides. Course, there's http://www.celexa.com Per the site: You may start to feel relief from some symptoms, such as depressed mood, after taking Celexa for only one week. Most people can expect to feel the full benefits of Celexa in four weeks. It is important to continue taking Celexa even if you begin to feel relief from your depression. Be patient. You didn't suddenly become depressed, and full recovery takes time. Your doctor may ask you to keep taking Celexa long after your depression has been relieved, to help keep it from coming back. To get the most out of Celexa, always take your medication exactly as prescribed by your physician. Be sure to talk to your doctor promptly if you have any side effects when taking Celexa. A simple adjustment in dosage may be all that is required. Celexa is well tolerated by many people. The most frequent side effects reported with Celexa are nausea, dry mouth, drowsiness, insomnia, increased sweating, tremor, diarrhea, and problems with ejaculation. People taking Celexa generally do not suffer from insomnia, agitation, nervousness, or anxiety any more than people not taking Celexa. Furthermore, Celexa has not been associated with clinically significant weight changes. ------------------- some specifics the site mentioned: -------------------- CONTRAINDICATIONS Concomitant use in patients taking monoamine oxidase inhibitors (MAOI's) is contraindicated (see WARNINGS). Celexa is contraindicated in patients with a hypersensitivity to citalopram or any of the inactive ingredients in Celexa. WARNINGS Potential for Interaction with Monoamine Oxidase Inhibitors In patients receiving serotonin reuptake inhibitor drugs in combination with a monoamine oxidase inhibitor (MAOI), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma. These reactions have also been reported in patients who have recently discontinued SSRI treatment and have been started on a MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Furthermore, limited animal data on the effects of combined use of SSRI's and MAOI's suggest that these drugs may act synergistically to elevate blood pressure and evoke behavioral excitation. Therefore, it is recommended that Celexa should not be used in combination with a MAOI, or within 14 days of discontinuing treatment with a MAOI. Similarly, at least 14 days should be allowed after stopping Celexa before starting a MAOI. PRECAUTIONS General Hyponatremia Several cases of hyponatremia and SIADH (syndrome of inappropriate antidiuretic hormone secretion) have been reported in association with Celexa treatment. All patients with these events have recovered with discontinuation of Celexa and/or medical intervention. Activation of Mania/Hypomania In placebo-controlled trials of Celexa, some of which included patients with bipolar disorder, activation of mania/hypomania was reported in 0.2% of 1063 patients treated with Celexa and in none of the 446 patients treated with placebo. Activation of mania/hypomania has also been reported in a small proportion of patients with major affective disorders treated with other marketed antidepressants. As with all antidepressants, Celexa should be used cautiously in patients with a history of mania. Seizures Although anticonvulsant effects of citalopram have been observed in animal studies, Celexa has not been systematically evaluated in patients with a seizure disorder. These patients were excluded from clinical studies during the product's premarketing testing. In clinical trials of Celexa, seizures occurred in 0.3% of patients treated with Celexa (a rate of one patient per 98 years of exposure) and 0.5% of patients treated with placebo (a rate of one patient per 50 years of exposure). Like other antidepressants, Celexa should be introduced with care in patients with a history of seizure disorder. Suicide The possibility of a suicide attempt is inherent in depression and may persist until significant remission occurs. Close supervision of high risk patients should accompany initial drug therapy. Prescriptions for Celexa should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose. Interference with Cognitive and Motor Performance In studies in normal volunteers, Celexa in doses of 40 mg/day did not produce impairment of intellectual function or psychomotor performance. Because any psychoactive drug may impair judgement, thinking, or motor skills, however, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that Celexa therapy does not affect their ability to engage in such activities. Use in Patients with Concomitant Illness Clinical experience with Celexa in patients with certain concomitant systemic illnesses is limited. Caution is advisable in using Celexa in patients with diseases or conditions that produce altered metabolism or hemodynamic responses. Celexa has not been systematically evaluated in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were generally excluded from clinical studies during the product's premarketing testing. However, the electrocardiograms of 1116 patients who received Celexa in clinical trials were evaluated and the data indicate that Celexa is not associated with the development of clinically significant ECG abnormalities. In subjects with hepatic impairment, citalopram clearance was decreased and plasma concentrations were increased. The use of Celexa in hepatically impaired patients should be approached with caution and a lower maximum dosage is recommended (see DOSAGE AND ADMINISTRATION). Because citalopram is extensively metabolized, excretion of unchanged drug in urine is a minor route of elimination. Until adequate numbers of patients with severe renal impairment have been evaluated during chronic treatment with Celexa, however, it should be used with caution in such patients (see DOSAGE AND ADMINISTRATION). Information for Patients Physicians are advised to discuss the following issues with patients for whom they prescribe Celexa. Although in controlled studies Celexa has not been shown to impair psychomotor performance, any psychoactive drug may impair judgment, thinking or motor skills, and so patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that Celexa therapy does not affect their ability to engage in such activities. Patients should be told that, although Celexa has not been shown in experiments with normal subjects to increase the mental and motor skill impairments caused by alcohol, the concomitant use of Celexa and alcohol in depressed patients is not advised. Patients should be advised to inform their physician if they are taking, or plan to take, any prescription or over-the-counter drugs, as there is a potential for interactions. Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during therapy. Patients should be advised to notify their physician if they are breast feeding an infant. While patients may notice improvement with Celexa therapy in 1 to 4 weeks, they should be advised to continue therapy as directed. Laboratory Tests There are no specific laboratory tests recommended. Drug Interactions CNS Drugs - Given the primary CNS effects of citalopram, caution should be used when it is taken in combination with other centrally acting drugs. Alcohol - Although citalopram did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by depressed patients taking Celexa is not recommended. Monoamine Oxidase Inhibitors (MAOI's) - See CONTRAINDICATIONS and WARNINGS. Cimetidine - In subjects who had received 21 days of 40 mg/day Celexa, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively. The clinical significance of these findings is unknown. Digoxin - In subjects who had received 21 days of 40 mg/day Celexa, combined administration of Celexa and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin. Lithium - Coadministration of Celexa (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or lithium. Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to the lithium dose in accordance with standard clinical practice. Because lithium may enhance the serotonergic effects of citalopram, caution should be exercised when Celexa and lithium are coadministered. Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan. If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram) is clinically warranted, appropriate observation of the patient is advised. Warfarin - Administration of 40 mg/day Celexa for 21 days did not affect the pharmacokinetics of warfarin, a CYP3A4 substrate. Prothrombin time was increased by 5%, the clinical significance of which is unknown. Carbamazepine - Combined administration of Celexa (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate. Although trough citalopram plasma levels were unaffected, given the enzyme inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of citalopram should be considered if the two drugs are coadministered. CYP3A4 and 2C19 Inhibitors - In vitro studies indicated that CYP3A4 and 2C19 are the primary enzymes involved in the metabolism of citalopram. As data are not available from clinical pharmacokinetic studies, the possibility that the clearance of citalopram will be decreased when citalopram is administered with a potent inhibitor of CYP3A4 (e.g., ketoconazole, itraconazole, fluconazole, or erythromycin), or a potent inhibitor of CYP2C19 (e.g., omeprazole), should be considered. Metoprolol - Administration of 40 mg/day Celexa for 22 days resulted in a two-fold increase in the plasma levels of the beta-adrenergic blocker metoprolol. Increased metoprolol plasma levels have been associated with decreased cardioselectivity. Coadministration of Celexa and metoprolol had no clinically significant effects on blood pressure or heart rate. Imipramine and Other Tricyclic Antidepressants (TCAs) - In vitro studies suggest that citalopram is a relatively weak inhibitor of CYP2D6. Coadministration of Celexa (40 mg/day for 10 days) with the tricyclic antidepressant imipramine (single dose of 100 mg), a substrate for CYP2D6, did not significantly affect the plasma concentrations of imipramine or citalopram. However, the concentration of the imipramine metabolite desipramine was increased by approximately 50%. The clinical significance of the desipramine change is unknown. Nevertheless, caution is indicated in the coadministration of TCA's with Celexa. Electroconvulsive Therapy (ECT) - There are no clinical studies of the combined use of electroconvulsive therapy (ECT) and Celexa. Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Citalopram was administered in the diet to NMRI/BOM strain mice and COBS WI strain rats for 18 and 24 months, respectively. There was no evidence for carcinogenicity of citalopram in mice receiving up to 240 mg/kg/day, which is equivalent to 20 times the maximum recommended human daily dose (MRHD) of 60 mg on a surface area (mg/m2) basis. There was an increased incidence of small intestine carcinoma in rats receiving 8 or 24 mg/kg/day, doses which are approximately 1.3 and 4 times the MRHD, respectively, on a mg/m2 basis. A no-effect dose for this finding was not established. The relevance of these findings to humans is unknown. Mutagenesis Citalopram was mutagenic in the in vitrobacterial reverse mutation assay (Ames test) in 2 of 5 bacterial strains (Salmonella TA98 and TA1537) in the absence of metabolic activation. It was clastogenic in the in vitro Chinese hamster lung cell assay for chromosomal aberrations in the presence and absence of metabolic activation. Citalopram was not mutagenic in the in vitro mammalian forward gene mutation assay (HPRT) in mouse lymphoma cells or in a coupled in vitro/in vivo unscheduled DNA synthesis (UDS) assay in rat liver. It was not clastogenic in the in vitro chromosomal aberration assay in human lymphocytes or in two in vivo mouse micronucleus assays. Impairment of Fertility When citalopram was administered orally to male and female rats prior to and throughout mating and gestation at doses of 16/24 (males/females), 32, 48, and 72 mg/kg/day, mating was decreased at all doses, and fertility was decreased at doses >32 mg/kg/day, approximately 5 times the maximum recommended human dose (MRHD) of 60 mg/day on a body surface area (mg/m2) basis. Gestation duration was increased at 48 mg/kg/day, approximately 8 times the MRHD. Pregnancy Pregnancy Category C In animal reproduction studies, citalopram has been shown to have adverse effects on embryo/fetal and postnatal development, including teratogenic effects, when administered at doses greater than human therapeutic doses. In two rat embryo/fetal development studies, oral administration of citalopram (32, 56, or 112 mg/kg/day) to pregnant animals during the period of organogenesis resulted in decreased embryo/fetal growth and survival and an increased incidence of fetal abnormalities (including cardiovascular and skeletal defects) at the high dose, which is approximately 18 times the maximum recommended human dose (MRHD) of 60 mg/day on a body surface area (mg/m2) basis. This dose was also associated with maternal toxicity (clinical signs, decreased BW gain). The developmental no effect dose of 56 mg/kg/day is approximately 9 times the MRHD on a mg/m2 basis. In a rabbit study, no adverse effects on embryo/fetal development were observed at doses of up to 16 mg/kg/day, or approximately 5 times the MRHD on a mg/m2 basis. Thus, teratogenic effects were observed at a maternally toxic dose in the rat and were not observed in the rabbit. When female rats were treated with citalopram (4.8, 12.8, or 32 mg/kg/day) from late gestation through weaning, increased offspring mortality during the first 4 days after birth and persistent offspring growth retardation were observed at the highest dose, which is approximately 5 times the MRHD on a mg/m2 basis. The no effect dose of 12.8 mg/kg/day is approximately 2 times the MRHD on a mg/m2 basis. Similar effects on offspring mortality and growth were seen when dams were treated throughout gestation and early lactation at doses >24 mg/kg/day, approximately 4 times the MRHD on a mg/m2 basis. A no effect dose was not determined in that study. There are no adequate and well-controlled studies in pregnant women; therefore, citalopram should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. ------------------------------------ / Alley alleypat@... oshidori@... http://www.alleypat.com My ICQ#:12631861 I can't think of a worse way to start a day than by waking up Quote Link to comment Share on other sites More sharing options...
Guest guest Posted March 20, 2001 Report Share Posted March 20, 2001 Hey Lora, I took Celexa for a while. I was on treatment and it didn't seem like it was enough for me so I changed. But it is right for many people and from what I've heard, has very few sides. Course, there's http://www.celexa.com Per the site: You may start to feel relief from some symptoms, such as depressed mood, after taking Celexa for only one week. Most people can expect to feel the full benefits of Celexa in four weeks. It is important to continue taking Celexa even if you begin to feel relief from your depression. Be patient. You didn't suddenly become depressed, and full recovery takes time. Your doctor may ask you to keep taking Celexa long after your depression has been relieved, to help keep it from coming back. To get the most out of Celexa, always take your medication exactly as prescribed by your physician. Be sure to talk to your doctor promptly if you have any side effects when taking Celexa. A simple adjustment in dosage may be all that is required. Celexa is well tolerated by many people. The most frequent side effects reported with Celexa are nausea, dry mouth, drowsiness, insomnia, increased sweating, tremor, diarrhea, and problems with ejaculation. People taking Celexa generally do not suffer from insomnia, agitation, nervousness, or anxiety any more than people not taking Celexa. Furthermore, Celexa has not been associated with clinically significant weight changes. ------------------- some specifics the site mentioned: -------------------- CONTRAINDICATIONS Concomitant use in patients taking monoamine oxidase inhibitors (MAOI's) is contraindicated (see WARNINGS). Celexa is contraindicated in patients with a hypersensitivity to citalopram or any of the inactive ingredients in Celexa. WARNINGS Potential for Interaction with Monoamine Oxidase Inhibitors In patients receiving serotonin reuptake inhibitor drugs in combination with a monoamine oxidase inhibitor (MAOI), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma. These reactions have also been reported in patients who have recently discontinued SSRI treatment and have been started on a MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Furthermore, limited animal data on the effects of combined use of SSRI's and MAOI's suggest that these drugs may act synergistically to elevate blood pressure and evoke behavioral excitation. Therefore, it is recommended that Celexa should not be used in combination with a MAOI, or within 14 days of discontinuing treatment with a MAOI. Similarly, at least 14 days should be allowed after stopping Celexa before starting a MAOI. PRECAUTIONS General Hyponatremia Several cases of hyponatremia and SIADH (syndrome of inappropriate antidiuretic hormone secretion) have been reported in association with Celexa treatment. All patients with these events have recovered with discontinuation of Celexa and/or medical intervention. Activation of Mania/Hypomania In placebo-controlled trials of Celexa, some of which included patients with bipolar disorder, activation of mania/hypomania was reported in 0.2% of 1063 patients treated with Celexa and in none of the 446 patients treated with placebo. Activation of mania/hypomania has also been reported in a small proportion of patients with major affective disorders treated with other marketed antidepressants. As with all antidepressants, Celexa should be used cautiously in patients with a history of mania. Seizures Although anticonvulsant effects of citalopram have been observed in animal studies, Celexa has not been systematically evaluated in patients with a seizure disorder. These patients were excluded from clinical studies during the product's premarketing testing. In clinical trials of Celexa, seizures occurred in 0.3% of patients treated with Celexa (a rate of one patient per 98 years of exposure) and 0.5% of patients treated with placebo (a rate of one patient per 50 years of exposure). Like other antidepressants, Celexa should be introduced with care in patients with a history of seizure disorder. Suicide The possibility of a suicide attempt is inherent in depression and may persist until significant remission occurs. Close supervision of high risk patients should accompany initial drug therapy. Prescriptions for Celexa should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose. Interference with Cognitive and Motor Performance In studies in normal volunteers, Celexa in doses of 40 mg/day did not produce impairment of intellectual function or psychomotor performance. Because any psychoactive drug may impair judgement, thinking, or motor skills, however, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that Celexa therapy does not affect their ability to engage in such activities. Use in Patients with Concomitant Illness Clinical experience with Celexa in patients with certain concomitant systemic illnesses is limited. Caution is advisable in using Celexa in patients with diseases or conditions that produce altered metabolism or hemodynamic responses. Celexa has not been systematically evaluated in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were generally excluded from clinical studies during the product's premarketing testing. However, the electrocardiograms of 1116 patients who received Celexa in clinical trials were evaluated and the data indicate that Celexa is not associated with the development of clinically significant ECG abnormalities. In subjects with hepatic impairment, citalopram clearance was decreased and plasma concentrations were increased. The use of Celexa in hepatically impaired patients should be approached with caution and a lower maximum dosage is recommended (see DOSAGE AND ADMINISTRATION). Because citalopram is extensively metabolized, excretion of unchanged drug in urine is a minor route of elimination. Until adequate numbers of patients with severe renal impairment have been evaluated during chronic treatment with Celexa, however, it should be used with caution in such patients (see DOSAGE AND ADMINISTRATION). Information for Patients Physicians are advised to discuss the following issues with patients for whom they prescribe Celexa. Although in controlled studies Celexa has not been shown to impair psychomotor performance, any psychoactive drug may impair judgment, thinking or motor skills, and so patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that Celexa therapy does not affect their ability to engage in such activities. Patients should be told that, although Celexa has not been shown in experiments with normal subjects to increase the mental and motor skill impairments caused by alcohol, the concomitant use of Celexa and alcohol in depressed patients is not advised. Patients should be advised to inform their physician if they are taking, or plan to take, any prescription or over-the-counter drugs, as there is a potential for interactions. Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during therapy. Patients should be advised to notify their physician if they are breast feeding an infant. While patients may notice improvement with Celexa therapy in 1 to 4 weeks, they should be advised to continue therapy as directed. Laboratory Tests There are no specific laboratory tests recommended. Drug Interactions CNS Drugs - Given the primary CNS effects of citalopram, caution should be used when it is taken in combination with other centrally acting drugs. Alcohol - Although citalopram did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by depressed patients taking Celexa is not recommended. Monoamine Oxidase Inhibitors (MAOI's) - See CONTRAINDICATIONS and WARNINGS. Cimetidine - In subjects who had received 21 days of 40 mg/day Celexa, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively. The clinical significance of these findings is unknown. Digoxin - In subjects who had received 21 days of 40 mg/day Celexa, combined administration of Celexa and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin. Lithium - Coadministration of Celexa (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or lithium. Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to the lithium dose in accordance with standard clinical practice. Because lithium may enhance the serotonergic effects of citalopram, caution should be exercised when Celexa and lithium are coadministered. Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan. If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram) is clinically warranted, appropriate observation of the patient is advised. Warfarin - Administration of 40 mg/day Celexa for 21 days did not affect the pharmacokinetics of warfarin, a CYP3A4 substrate. Prothrombin time was increased by 5%, the clinical significance of which is unknown. Carbamazepine - Combined administration of Celexa (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate. Although trough citalopram plasma levels were unaffected, given the enzyme inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of citalopram should be considered if the two drugs are coadministered. CYP3A4 and 2C19 Inhibitors - In vitro studies indicated that CYP3A4 and 2C19 are the primary enzymes involved in the metabolism of citalopram. As data are not available from clinical pharmacokinetic studies, the possibility that the clearance of citalopram will be decreased when citalopram is administered with a potent inhibitor of CYP3A4 (e.g., ketoconazole, itraconazole, fluconazole, or erythromycin), or a potent inhibitor of CYP2C19 (e.g., omeprazole), should be considered. Metoprolol - Administration of 40 mg/day Celexa for 22 days resulted in a two-fold increase in the plasma levels of the beta-adrenergic blocker metoprolol. Increased metoprolol plasma levels have been associated with decreased cardioselectivity. Coadministration of Celexa and metoprolol had no clinically significant effects on blood pressure or heart rate. Imipramine and Other Tricyclic Antidepressants (TCAs) - In vitro studies suggest that citalopram is a relatively weak inhibitor of CYP2D6. Coadministration of Celexa (40 mg/day for 10 days) with the tricyclic antidepressant imipramine (single dose of 100 mg), a substrate for CYP2D6, did not significantly affect the plasma concentrations of imipramine or citalopram. However, the concentration of the imipramine metabolite desipramine was increased by approximately 50%. The clinical significance of the desipramine change is unknown. Nevertheless, caution is indicated in the coadministration of TCA's with Celexa. Electroconvulsive Therapy (ECT) - There are no clinical studies of the combined use of electroconvulsive therapy (ECT) and Celexa. Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Citalopram was administered in the diet to NMRI/BOM strain mice and COBS WI strain rats for 18 and 24 months, respectively. There was no evidence for carcinogenicity of citalopram in mice receiving up to 240 mg/kg/day, which is equivalent to 20 times the maximum recommended human daily dose (MRHD) of 60 mg on a surface area (mg/m2) basis. There was an increased incidence of small intestine carcinoma in rats receiving 8 or 24 mg/kg/day, doses which are approximately 1.3 and 4 times the MRHD, respectively, on a mg/m2 basis. A no-effect dose for this finding was not established. The relevance of these findings to humans is unknown. Mutagenesis Citalopram was mutagenic in the in vitrobacterial reverse mutation assay (Ames test) in 2 of 5 bacterial strains (Salmonella TA98 and TA1537) in the absence of metabolic activation. It was clastogenic in the in vitro Chinese hamster lung cell assay for chromosomal aberrations in the presence and absence of metabolic activation. Citalopram was not mutagenic in the in vitro mammalian forward gene mutation assay (HPRT) in mouse lymphoma cells or in a coupled in vitro/in vivo unscheduled DNA synthesis (UDS) assay in rat liver. It was not clastogenic in the in vitro chromosomal aberration assay in human lymphocytes or in two in vivo mouse micronucleus assays. Impairment of Fertility When citalopram was administered orally to male and female rats prior to and throughout mating and gestation at doses of 16/24 (males/females), 32, 48, and 72 mg/kg/day, mating was decreased at all doses, and fertility was decreased at doses >32 mg/kg/day, approximately 5 times the maximum recommended human dose (MRHD) of 60 mg/day on a body surface area (mg/m2) basis. Gestation duration was increased at 48 mg/kg/day, approximately 8 times the MRHD. Pregnancy Pregnancy Category C In animal reproduction studies, citalopram has been shown to have adverse effects on embryo/fetal and postnatal development, including teratogenic effects, when administered at doses greater than human therapeutic doses. In two rat embryo/fetal development studies, oral administration of citalopram (32, 56, or 112 mg/kg/day) to pregnant animals during the period of organogenesis resulted in decreased embryo/fetal growth and survival and an increased incidence of fetal abnormalities (including cardiovascular and skeletal defects) at the high dose, which is approximately 18 times the maximum recommended human dose (MRHD) of 60 mg/day on a body surface area (mg/m2) basis. This dose was also associated with maternal toxicity (clinical signs, decreased BW gain). The developmental no effect dose of 56 mg/kg/day is approximately 9 times the MRHD on a mg/m2 basis. In a rabbit study, no adverse effects on embryo/fetal development were observed at doses of up to 16 mg/kg/day, or approximately 5 times the MRHD on a mg/m2 basis. Thus, teratogenic effects were observed at a maternally toxic dose in the rat and were not observed in the rabbit. When female rats were treated with citalopram (4.8, 12.8, or 32 mg/kg/day) from late gestation through weaning, increased offspring mortality during the first 4 days after birth and persistent offspring growth retardation were observed at the highest dose, which is approximately 5 times the MRHD on a mg/m2 basis. The no effect dose of 12.8 mg/kg/day is approximately 2 times the MRHD on a mg/m2 basis. Similar effects on offspring mortality and growth were seen when dams were treated throughout gestation and early lactation at doses >24 mg/kg/day, approximately 4 times the MRHD on a mg/m2 basis. A no effect dose was not determined in that study. There are no adequate and well-controlled studies in pregnant women; therefore, citalopram should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. ------------------------------------ / Alley alleypat@... oshidori@... http://www.alleypat.com My ICQ#:12631861 I can't think of a worse way to start a day than by waking up Quote Link to comment Share on other sites More sharing options...
Guest guest Posted March 20, 2001 Report Share Posted March 20, 2001 New Study Shows Celexa Patients Experience Significantly Less Weight Gain Than Those on Paxil® - 2/13/2001 10:34:00 AM SAN JUAN, Puerto Rico, Dec. 15 /PRNewswire/ -- Clinically significant body weight gain is five times more prevalent with Paxil (paroxetine HCl) than Celexa (citalopram HBr), according to a major new study of patients treated for depression and anxiety. The study involving the two selective serotonin reuptake inhibitors (SSRIs) was presented by University of Wisconsin researchers at the American College of Neuropsychopharmacology Annual Meeting in San . " Though they all belong to the same category of antidepressants, SSRIs have significant structural and clinical differences, including side effects, " says W. Jefferson, MD, clinical professor of psychiatry, University of Wisconsin Medical School, and lead investigator of the study. " Evaluating weight gain was a primary focus of this study due to the serious emotional role it can play in the patient's life and the relative lack of data available on the subject. " Similar efficacy, different weight gain In the 28-week, randomized, double-blind, parallel group study, citalopram and paroxetine produced significant improvements of similar magnitude on measures of anxiety and depression among 104 adult male and female participants (18-65 years of age). However, clinically significant body weight gain occurred among 21.6% of paroxetine-treated patients compared to 3.9% of citalopram-treated patients. Clinically significant body weight gain was defined in this study as greater than or equal to 7% increase. " Weight gain is an extremely important factor in evaluating SSRIs, " notes Dr. Jefferson. " A weight gain of seven percent or more is considerable for a patient who is suffering from depression and anxiety. This physical change may lead a patient to make a unilateral decision to end treatment. " Other adverse effects reported in the study During the post-medication follow-up period of the study comparing citalopram and paroxetine, the paroxetine group exhibited a trend towards more dizziness, headache, and nausea -- adverse events that may be associated with a discontinuation syndrome. The two-week post-medication period was the last part of the study design that consisted of a one-week single-blind placebo lead-in period, followed by a 24-week double-blind treatment period, and a two-week double-blind down-titration period. Dosing started at 20 mg/day and could be titrated (based on response and tolerability) up to 40 mg/day for either drug. All patients enrolled in the study had a diagnosis of Major Depression and Mixed Anxiety Depressive Disorder (according to DSM-IV) and were required to score at a certain level on two different depression and anxiety ratings scales. About W. Jefferson, M.D. W. Jefferson, M.D. is clinical professor of psychiatry, University of Wisconsin Medical School, and distinguished senior scientist, Madison Institute of Medicine. He is also president of Healthcare Technology Systems, Madison, WI. His major clinical and research interests are in mood and anxiety disorders and psychopharmacology and the medical/psychiatry interface. In addition to numerous articles in professional journals and chapters in books, he has co-authored books such as the " Handbook of Medical Psychiatry, " " Depression and Its Treatment, " and " Primer of Lithium Therapy. " Dr. Jefferson is board certified in both psychiatry and internal medicine. He received his medical degree from the University of Wisconsin. About Celexa (citalopram) Celexa, marketed by Forest Laboratories Inc. (NYSE: FRX), has been shown to be safe and effective in many large-scale clinical trials involving patients with mild to moderate depression. Celexa has little to no potential to inhibit the metabolism of other drugs. More than 20 million patients have been prescribed Celexa, which currently is available in 69 countries. Among Celexa-treated patients in clinical trials reporting side effects, those most frequently reported were nausea, dry mouth, and sleepiness. As with all SSRIs, Celexa should not be taken together with monoamine oxidase inhibitors. Developed by the Danish pharmaceutical firm H. Lundbeck AS, citalopram is marketed in Europe as Cipramil®. Celexa is the fastest-growing SSRI in the United States and is the top-selling antidepressant in 13 countries in which three or more SSRIs are available. Full prescribing information can be found on the Internet at www.celexa.com. SOURCE Forest Laboratories Inc. / Alley alleypat@... oshidori@... http://www.alleypat.com My ICQ#:12631861 I can't think of a worse way to start a day than by waking up Quote Link to comment Share on other sites More sharing options...
Guest guest Posted March 20, 2001 Report Share Posted March 20, 2001 New Study Shows Celexa Patients Experience Significantly Less Weight Gain Than Those on Paxil® - 2/13/2001 10:34:00 AM SAN JUAN, Puerto Rico, Dec. 15 /PRNewswire/ -- Clinically significant body weight gain is five times more prevalent with Paxil (paroxetine HCl) than Celexa (citalopram HBr), according to a major new study of patients treated for depression and anxiety. The study involving the two selective serotonin reuptake inhibitors (SSRIs) was presented by University of Wisconsin researchers at the American College of Neuropsychopharmacology Annual Meeting in San . " Though they all belong to the same category of antidepressants, SSRIs have significant structural and clinical differences, including side effects, " says W. Jefferson, MD, clinical professor of psychiatry, University of Wisconsin Medical School, and lead investigator of the study. " Evaluating weight gain was a primary focus of this study due to the serious emotional role it can play in the patient's life and the relative lack of data available on the subject. " Similar efficacy, different weight gain In the 28-week, randomized, double-blind, parallel group study, citalopram and paroxetine produced significant improvements of similar magnitude on measures of anxiety and depression among 104 adult male and female participants (18-65 years of age). However, clinically significant body weight gain occurred among 21.6% of paroxetine-treated patients compared to 3.9% of citalopram-treated patients. Clinically significant body weight gain was defined in this study as greater than or equal to 7% increase. " Weight gain is an extremely important factor in evaluating SSRIs, " notes Dr. Jefferson. " A weight gain of seven percent or more is considerable for a patient who is suffering from depression and anxiety. This physical change may lead a patient to make a unilateral decision to end treatment. " Other adverse effects reported in the study During the post-medication follow-up period of the study comparing citalopram and paroxetine, the paroxetine group exhibited a trend towards more dizziness, headache, and nausea -- adverse events that may be associated with a discontinuation syndrome. The two-week post-medication period was the last part of the study design that consisted of a one-week single-blind placebo lead-in period, followed by a 24-week double-blind treatment period, and a two-week double-blind down-titration period. Dosing started at 20 mg/day and could be titrated (based on response and tolerability) up to 40 mg/day for either drug. All patients enrolled in the study had a diagnosis of Major Depression and Mixed Anxiety Depressive Disorder (according to DSM-IV) and were required to score at a certain level on two different depression and anxiety ratings scales. About W. Jefferson, M.D. W. Jefferson, M.D. is clinical professor of psychiatry, University of Wisconsin Medical School, and distinguished senior scientist, Madison Institute of Medicine. He is also president of Healthcare Technology Systems, Madison, WI. His major clinical and research interests are in mood and anxiety disorders and psychopharmacology and the medical/psychiatry interface. In addition to numerous articles in professional journals and chapters in books, he has co-authored books such as the " Handbook of Medical Psychiatry, " " Depression and Its Treatment, " and " Primer of Lithium Therapy. " Dr. Jefferson is board certified in both psychiatry and internal medicine. He received his medical degree from the University of Wisconsin. About Celexa (citalopram) Celexa, marketed by Forest Laboratories Inc. (NYSE: FRX), has been shown to be safe and effective in many large-scale clinical trials involving patients with mild to moderate depression. Celexa has little to no potential to inhibit the metabolism of other drugs. More than 20 million patients have been prescribed Celexa, which currently is available in 69 countries. Among Celexa-treated patients in clinical trials reporting side effects, those most frequently reported were nausea, dry mouth, and sleepiness. As with all SSRIs, Celexa should not be taken together with monoamine oxidase inhibitors. Developed by the Danish pharmaceutical firm H. Lundbeck AS, citalopram is marketed in Europe as Cipramil®. Celexa is the fastest-growing SSRI in the United States and is the top-selling antidepressant in 13 countries in which three or more SSRIs are available. Full prescribing information can be found on the Internet at www.celexa.com. SOURCE Forest Laboratories Inc. / Alley alleypat@... oshidori@... http://www.alleypat.com My ICQ#:12631861 I can't think of a worse way to start a day than by waking up Quote Link to comment Share on other sites More sharing options...
Guest guest Posted March 20, 2001 Report Share Posted March 20, 2001 Alley, You are a life saver. Thank you soo much for the information. I am so grateful. I can't believe that you only have six more weeks left! I remember when you started treatment, and how happy I was that you were not experienceing sides like some of the others. Thank you, thank you, thank you.... Staying positive, Lora Quote Link to comment Share on other sites More sharing options...
Guest guest Posted March 20, 2001 Report Share Posted March 20, 2001 Alley, You are a life saver. Thank you soo much for the information. I am so grateful. I can't believe that you only have six more weeks left! I remember when you started treatment, and how happy I was that you were not experienceing sides like some of the others. Thank you, thank you, thank you.... Staying positive, Lora Quote Link to comment Share on other sites More sharing options...
Guest guest Posted March 21, 2001 Report Share Posted March 21, 2001 Lora, I was on Celexa but I quit taking it on my own. Only thing it seemed to do to me was give me Vertigo. But everyone is different. I have some Valerian Root, that really seems to be helping me to sleep. I think it is ok to take.... Smile, Connie __________________________________________________ Quote Link to comment Share on other sites More sharing options...
Guest guest Posted March 22, 2001 Report Share Posted March 22, 2001 Thanks connie, I took one pill Tuesday night, but Wednesday I could not function, soo tired. I am leaving to go out of town tomorrow, so decided to try again when I get back. A friend of mine also had vertigo with it......hmmmmmmm. Staying positive, Lora Quote Link to comment Share on other sites More sharing options...
Guest guest Posted March 22, 2001 Report Share Posted March 22, 2001 Thanks connie, I took one pill Tuesday night, but Wednesday I could not function, soo tired. I am leaving to go out of town tomorrow, so decided to try again when I get back. A friend of mine also had vertigo with it......hmmmmmmm. Staying positive, Lora Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.